Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas

Cancer Immunology, Immunotherapy

Volumn 54, Issue 9, 2005, Pages 915-925

  Plate, Janet M D ^a   Plate, Aileen E ^a   Shott, Susan ^a   Bograd, Susan ^a   Harris, Jules E ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adenocarcinoma; Gemcitabine; Pancreas

Indexed keywords

B7 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD45RO ANTIGEN; CD86 ANTIGEN; CYTOKINE; GAMMA INTERFERON; GEMCITABINE; INTERLEUKIN 2 RECEPTOR ALPHA;

ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DENDRITIC CELL; ENZYME LINKED IMMUNOSPOT ASSAY; FUNCTIONAL ASSESSMENT; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LYMPHOCYTE COUNT; MEMORY CELL; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; STAINING; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE; TUMOR IMMUNITY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTIGEN-PRESENTING CELLS; ANTIMETABOLITES, ANTINEOPLASTIC; B-LYMPHOCYTES; CD4-CD8 RATIO; DENDRITIC CELLS; DEOXYCYTIDINE; FEMALE; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RIBONUCLEOTIDE REDUCTASES; T-LYMPHOCYTES;

EID: 22244489353     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-004-0638-1     Document Type: Article

References (24)

1. Plate JM, Harris JE (2000) Immune cell functions in pancreatic cancer. Crit Rev Immunol 20:375
2. Plate JM, Shott S, Harris JE (1999) Immunoregulation in pancreatic cancer patients. Cancer Immunol Immunother 48:270
3. Alvino E, Fuggetta MP, Tricarico M, Bonmassar E (1998) 2′-2′-difluorodeoxycytidine: in vitro effects on cell-mediated immune response. Anticancer Res 18:3597
4. Daikeler T, Maas K, Hartmann JT, Kanz L, Bokemeyer C (1997) Weekly short infusions of gemcitabine are not associated with suppression of lymphatic activity in patients with solid tumors. Anticancer Drugs 8:643
5. Nowak AK, Lake RA, Marzo AL, Scott B, Heath WR, Collins EJ, Frelinger JA, Robinson BW (2003) Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol 170:4905
6. Nowak AK, Robinson BW, Lake RA (2003) Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 63:4490
7. Heiser A, Dahm P, Yancey DR, Maurice MA, Boczkowski D, Nair SK, Gilboa E, Vieweg J (2000) Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J Immunol 164:5508
8. Heiser A, Maurice MA, Yancey DR, Coleman DM, Dahm P, Vieweg J (2001) Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors. Cancer Res 61:3388
9. Plate JM, Petersen KS, Buckingham L, Shahidi H, Schofield CM (2000) Gene expression in chronic lymphocytic leukemia B cells and changes during induction of apoptosis. Exp Hematol 28:1214
10. Heeger PS, Greenspan NS, Kuhlenschmidt S, Dejelo C, Hricik DE, Schulak JA, Tary-Lehmann M (1999) Pretransplant frequency of donor-specific, IFN-gamma-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes. J Immunol 163:2267
11. McCoy JP Jr, Overton WR (1994) Quality control in flow cytometry for diagnostic pathology: II. A conspectus of reference ranges for lymphocyte immunophenotyping. Cytometry 18:129
12. Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA (2001) CD4 + CD25high regulatory cells in human peripheral blood. J Immunol 167:1245
13. Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G (2001) Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med 193:1303
14. Jonuleit H, Schmitt E (2003) The regulatory T cell family: distinct subsets and their interrelations. J Immunol 171:6323
15. Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH (2001) Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med 193:1285
16. Bartido SM, Zier K (2003) T-cell responses to multiple antigens presented by RNA-transfected APCs: a possible immunomonitoring tool. Cancer Immunol Immunother 53:100
17. Minami T, Nakanishi Y, Izumi M, Harada T, Hara N (2003) Enhancement of antigen-presenting capacity and antitumor immunity of dendritic cells pulsed with autologous tumor-derived RNA in mice. J Immunother 26:420
18. Morse MA, Nair SK, Mosca PJ, Hobeika AC, Clay TM, Deng Y, Boczkowski D, Proia A, Neidzwiecki D, Clavien PA, Hurwitz HI, Schlom J, Gilboa E, Lyerly HK (2003) Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA. Cancer Invest 21:341
19. Nair S, Boczkowski D (2002) RNA-transfected dendritic cells. Expert Rev Vaccines 1:507
20. Amlot PL, Tahami F, Chinn D, Rawlings E (1996) Activation antigen expression on human T cells. I. Analysis by two-colour flow cytometry of umbilical cord blood, adult blood and lymphoid tissue. Clin Exp Immunol 105:176
21. Biselli R, Matricardi PM, D'Amelio R, Fattorossi A (1992) Multiparametric flow cytometric analysis of the kinetics of surface molecule expression after polyclonal activation of human peripheral blood T lymphocytes. Scand J Immunol 35:439
22. Ziegler SF, Ramsdell F, Alderson MR (1994) The activation antigen CD69. Stem Cells 12:456
23. Nowak AK, Robinson BW, Lake RA (2002) Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. Cancer Res 62:2353
24. Plate JMD, Harris JE (2004) Effects of gemcitabine treatment on immune cells and functions in pancreatic cancer patients. Proc Am Assoc Cancer Res 45:500